Sporotrichosis in dogs: epidemiological and clinical-therapeutic profile and the emergence of itraconazole-resistant isolates

• Published in: Medical mycology (Oxford) 2022-12, Vol.60 (12)
• Main Authors: Baes Pereira, Sergiane, dos Reis Gomes, Angelita, Bressan Waller, Stefanie, Batista Xavier, Jose Raphael, Messias Rodrigues, Anderson, Kutscher Ripoll, Márcia, Ferreira, Marcos Roberto Alves, Rochedo Conceição, Fabricio, Osório de Faria, Renata, Pascoti Bruhn, Fabio Raphael
• Format: Article
• Language: English
• ISSN: 1369-3786; 1460-2709
• DOI: 10.1093/mmy/myac089

Sporotrichosis is a neglected and emerging mycosis caused by the traumatic implantation of Sporothrix propagules into the (sub)cutaneous tissues of humans and animals. We evaluated canine sporotrichosis's clinical-therapeutic, epidemiological profile, and in vitro susceptibility of isolates to itraconazole. The variables were evaluated by a chi-square test. A total of 69 dogs were infected with Sporothrix spp., and the molecular identification revealed an overwhelming occurrence of S. brasiliensis as the etiological agent. The epidemiological profile was male (56.5%), adults (4.9 ± 1.92 years old; 69.6%), and mongrels (53.6%). The clinical signs were 76.8%, ulcers, draining tracts, and nodules were predominant, mainly in the nasal region (82.2%). Dogs were diagnosed late with an evolution time of up to 3 months (34.8%). According to the prior therapeutic information, 52.2% received empirical therapy, 79.2% antibiotics, and had a 0.29 significantly greater chance of presenting lesion evolution time ˃ 3 months (P